Research programme: postmyocardial infarction therapy - BioDiem

Drug Profile

Research programme: postmyocardial infarction therapy - BioDiem

Alternative Names: BDM-K; Postmyocardial infarction therapy research programme - BioDiem

Latest Information Update: 13 Apr 2007

Price : $50

At a glance

  • Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Postmyocardial infarction

Most Recent Events

  • 31 Dec 2006 No development reported - Preclinical for Postmyocardial infarction in Australia (PO)
  • 31 Dec 2006 No development reported - Clinical-Phase-Unknown for Postmyocardial infarction in Russia (PO)
  • 28 Sep 2004 Preclinical trials in Postmyocardial infarction in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top